Stock Financial Ratios


AGIO / Agios Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price59.64
Volume202,200.00
Market Cap ($M)2,862.50
Enterprise Value ($M)2,472.97
Book Value ($M)358.59
Book Value / Share9.16
Price / Book6.36
NCAV ($M)530.66
NCAV / Share13.56
Price / NCAV4.82
Income Statement (mra) ($M)
Revenue0.00
EBITDA-200.99
Net Income-198.47
Balance Sheet (mrq) ($M)
Cash & Equivalents132.74
Cash / Share3.39
Assets687.20
Liabilities237.39
Quick Ratio6.33
Current Ratio6.33
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.55
Return on Assets (ROA)-0.32
Return on Equity (ROE)-0.55
Identifiers and Descriptors
CUSIP00847X104
Central Index Key (CIK)1439222
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
00847X954
00847X904
Share Statistics
Common Shares Outstanding (M)48.75
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Per Share0.61
Liabilities Current Per Share2.25
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Current Per Share13.50
Liabilities And Stock Equity Per Share17.56
Cash Per Share3.39
Additional Paid In Capital Per Share29.65
Assets Other Current Per Share0.00
Equity Per Share11.50
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Intangibles Per Share0.00
Assets Other Non Current Per Share0.03
Retained Earnings Per Share-18.14
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Assets Per Share17.56
Assets Non Current Per Share0.00
Liabilities Per Share6.07
Inventory Per Share0.00
Cash And Equivalents Per Share3.39
Property Plant And Equipment Net Per Share0.61

Related News Stories

7 ‘Strong Buy’ Stocks With 100% Wall Street Support | InvestorPlace

2017-11-17 investorplace
Which hot stocks are Wall Street analysts the most bullish on? The top stocks with no “hold” or “sell” ratings and a pure “strong buy” analyst consensus rating. Such strong buy stocks make for the most compelling investment opportunities — and I recommend keeping a close eye on them as we roll into 2018. (257-1)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

36 Stocks For November 2017

2017-11-06 seekingalpha
Every month, we construct a theoretical long/short portfolio of stocks that demonstrates solid relative value with potential for ongoing cash flow growth and ROIC expansion. (703-0)

Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

2017-11-02 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) posted third-quarter 2017 loss of $1.59 per share, narrower than both the Zacks Consensus Estimate of a loss of $1.74 and the year-ago loss of $1.63. (100-0)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2017 Results - Earnings Call Transcript

2017-11-01 seekingalpha
Good morning and welcome to Agios' Third Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Kendra Adams, Senior Director, Investor and Public Relations. (9-0)

CUSIP: 00847X104